Health ❯ Healthcare ❯ Pharmaceuticals

Obesity Treatment

Wegovy GLP-1 Drugs GLP-1 Medications Weight Loss Drugs Semaglutide Weight Loss Medications Clinical Trials Novo Nordisk Mounjaro Tirzepatide CagriSema Oral Semaglutide Injectable Medications Patient Outcomes Oral Medications Mounjaro (Tirzepatida) Drug Development Medicaid Coverage Semaglutide Medicines Liraglutide Startup Companies Wegovy® Retatrutida Clinical-stage Candidates Medication Pricing Orforglipron Weight-loss Drugs Monlunabant GLP-1 Therapies Drug Recommendations Clinical Research Drug Efficacy GLP-1 Therapy Wegovy's Heart Benefits Ozempic Prescription Medications MariTide Drug Pricing Semaglutide Drugs

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

Sales were led by injectable GLP-1 treatments that now face pressure from cheaper pills.

Wegovy Pill Posts Strong U.S. Debut as U.K. Authorizes Higher 7.2 mg Injectable Dose

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Novo Nordisk Cuts 2025 Outlook and Names New CEO as Shares Plunge

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial